Latest Healthcare-associated pneumonia Stories
REINACH, Switzerland, Oct.
Arpida has announced that the European Medicines Agency has accepted for review its marketing authorization application for intravenous iclaprim. Arpida is seeking approval of intravenous iclaprim in the EU for the treatment of complicated skin and soft tissue infections (cSSTI).
REINACH, Switzerland, August 21 /PRNewswire-FirstCall/ -- Arpida Ltd. today announced that the European Medicines Agency (EMEA) has accepted for review its Marketing Authorisation Application (MAA) for intravenous iclaprim.
Arpida has submitted a marketing authorization application for intravenous iclaprim for the treatment of complicated skin and soft tissue infections to the European Medicines Agency.
Californians hospitalized with community-acquired pneumonia (CAP) could more than double their chances of survival if they are treated at one of the top-rated hospitals, according to a newly released report from the Office of Statewide Health Planning and Development (OSHPD), "Community Acquired Pneumonia: Hospital Outcomes in California, 2003-2005." In this third report on CAP quality of care, the report provides statistical analysis on the outcomes of 208,000 adult pneumonia patients...
Preliminary research from the Centers for Disease Control and Prevention (CDC) suggests that community acquired pneumonia (CAP) caused by the Staphylococcus aureus bacterium may be more common than originally suspected, including that caused by antibiotic resistant strains. Researchers report their findings today (March 19) at the 2008 International Conference on Emerging Infectious Diseases in Atlanta, Georgia.
A pneumonia vaccine seems to save the lives of older adults who become so ill that they are hospitalized, even if does not prevent them from getting pneumonia, researchers said on Wednesday.
- Emitting flashes of light; glittering.